News & InsightsNewsletterLegislation Hub

Foresight

Foresight
AboutContactBook DemoLog in
Start free trial
Foresight logo
All News & Insights

Pharmaceutical Firms Challenge EU Urban Wastewater Treatment Directive

General
20
June 2025
•
350
Dr Steven Brennan
Pharmaceutical firms challenge EU Urban Wastewater Treatment Directive over EPR costs, raising compliance concerns across the chemicals value chain.
Wastewater
Quick prompts

AI Generated

Get to the point quicker with prompts - a smarter way to get the information you need from our articles.

Summarise this article

Legal challenges to the UWWTD from 14 pharmaceutical firms spotlight growing tensions around extended producer responsibility. The outcomes could reshape how environmental costs are shared across the chemicals and manufacturing ecosystem.

What is the Urban Wastewater Treatment Directive (UWWTD)?

Why are pharmaceutical companies challenging the UWWTD?

They argue that the directive imposes unfair financial burdens, was adopted under the wrong legal basis, and risks limiting drug availability. The lawsuits aim to annul parts of the directive or its entirety.

AI Assistant

This feature and much more is available on our platform. If you would like early access, please leave your email and we'll get in touch.

We'll be in touch when the Assistant is ready.
Oops! Something went wrong while submitting the form.
Mountains

A coalition of fourteen pharmaceutical companies has filed lawsuits against the European Union’s Urban Wastewater Treatment Directive (UWWTD), adopted in November 2024. The legal actions, lodged in March 2025 before the General Court of the European Union, argue that the directive imposes disproportionate financial burdens on medicinal and cosmetic product manufacturers, potentially setting a precedent for extended producer responsibility (EPR) across multiple sectors.

Directive introduces EPR scheme for micropollutant removal

The contested UWWTD mandates quaternary treatment upgrades in urban wastewater plants to remove micropollutants, including pharmaceutical residues. Articles 9 and 10 of the directive establish an EPR scheme requiring relevant producers to cover up to 100% of associated costs. Pharmaceutical firms assert this policy violates legal and procedural norms under EU law, and that it targets their sector unfairly.

Plaintiffs such as Accord Healthcare, Zentiva, Teva, and Laboratorios Normon claim the directive was adopted using an incorrect legal basis under Article 192(1) of the Treaty on the Functioning of the European Union (TFEU), which applies to environmental matters. They argue that due to the fiscal nature of the obligations, Article 192(2)(a)—requiring unanimous Council approval—should have been used.

Implications across the manufacturing value chain

Beyond legal technicalities, the lawsuits underscore broader concerns about regulatory fairness and cost distribution. Producers argue the EPR scheme lacks clarity on implementation, including cost calculation methods and criteria for exemptions (e.g., “rapidly biodegradable” substances). Industry stakeholders also fear unintended consequences for public health, as the directive could disincentivise the development of vital pharmaceuticals, particularly where structural redesign of active ingredients is not viable.

Although no trade associations have joined the legal action, the coordinated filings suggest widespread concern across the sector. These cases will likely influence how future EU environmental regulations allocate responsibilities among stakeholders in pharmaceuticals, cosmetics, and beyond.

Next steps and regulatory outlook

A ruling by the General Court could redefine the scope of EPR obligations in EU legislation, shaping future compliance expectations for chemical-intensive industries. Companies across the manufacturing value chain should monitor developments closely and evaluate potential operational and legal impacts.

Read the source story

Read this article now for free!

You have read 3 articles.
Create a free account
or
Log in
to finish reading this article now.

Subscribe to our weekly digest

Sign up to receive our newsletter every Tuesday and get access to all of our content.

By creating an account, you agree to the Terms of Service and Privacy Policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
This is some text inside of a div block.

Trusted by professionals at

Dupont
ECHA - European Chemicals Agency
Energizer
Chemours
This is some text inside of a div block.

Get Foresight Today

Stay compliant, reduce risk, and protect your business with our AI-powered chemical policy monitoring—tailored just for you.

Global monitoring of 1,200+ sources
Expert-reviewed, trusted regulatory alerts
Instant risk identification for 350k+ substances

Ready to supercharge your policy monitoring workflow?

We’ll be in touch soon with more details and support to help you get started.
Oops! Something went wrong while submitting the form.
Share with a friend
Copy link

Related Articles

Office meetingGlobal Panel on Chemicals, Waste and Pollution Established to Guide Future Regulation

July 6, 2025

PlantsEU Reopens Glyphosate Carcinogenicity Review, Triggering Regulatory Reassessment

July 6, 2025

Americal Chemistry Council logoACC Reaffirms BPA Safety in Packaging Amid Growing Regulatory Scrutiny

July 7, 2025

Foresight regulatory experts
Streamline your chemical compliance
Easy-to-use product compliance management for small and mid-sized manufacturers — mitigate risk and protect market access.
Get started
Subscribe to Foresight's newsletter
Stay ahead with the latest news & insights
Join 1,000s of compliance professionals getting the latest insights right to their inbox for free, every Tuesday.
100% free. No spam. Unsubscribe any time.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Stay ahead with the latest news & insights
Subscribe to our free weekly newsletter covering news, events, and expert insights.

Related articles

Americal Chemistry Council logo

ACC Reaffirms BPA Safety in Packaging Amid Growing Regulatory Scrutiny

ACC asserts BPA safety in food packaging, backing FDA research. Learn what this means for manufacturers and the chemicals supply chain.

7

Jul 2025

General
European Parliament

EU Faces Scrutiny Over Inaction on Chemicals Strategy Commitments

A European Parliament report highlights the EU’s failure to deliver key chemicals strategy actions, affecting policy certainty across sectors.

6

Jul 2025

General
Plants

EU Reopens Glyphosate Carcinogenicity Review, Triggering Regulatory Reassessment

The EU has mandated a review of glyphosate’s carcinogenicity, impacting chemical compliance and risk assessments across multiple industries.

6

Jul 2025

General
Foresight
Providing critical insights, analysis, and guidance to help businesses anticipate changes, make informed decisions, and stay ahead.
News & Insights
Newsletter
Legislation Hub
Coverage
Contact
About
© 2025 Foresight. All rights reserved.
SitemapTerms of servicePrivacy policyCookie policy